Clinical Trial Update: Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients [Phase 2]

View source ↗

Summary

Phase 2 trial investigating brentuximab vedotin as a single agent for relapsed/refractory CD30+ peripheral T-cell lymphoma (PTCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphatic Diseases
• Peripheral T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Lymphatic Diseases | Phase 2 | Status: COMPLETED